Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats.

Abstract

AIM:

To validate the gubra DIO-rats as a useful animal model of human obesity.

METHODS:

The gubra diet-induced obesity (DIO) rat model was based on male Sprague-Dawley rats with ad libitum access to regular chow and a palatable diet rich in fat and sugar. To evaluate the versatility of the gubra DIO-rats as a valid model of human obesity syndrome, the efficacy of 2 weight loss compounds liraglutide and sibutramine with different mechanisms of action were examined in 7-month-old gubra DIO-rats. Liraglutide (200 μg/kg, sc) was administered bi-daily, and sibutramine (5 mg/kg, po) was administered once daily for 23 d.

RESULTS:

Both the compounds effectively reduced the food intake, body weight and total fat mass as measured by nuclear magnetic resonance. Whereas the 5-HT reuptake inhibitor/5-HT receptor agonist sibutramine reduced the intake of both chow and the gubra-diet, the GLP-1 analogue liraglutide predominantly reduced the intake of the highly palatable diet, indicating a shift in food preference. Sibutramine lowered the insulin sensitivity index, primarily via reductions in glucose-stimulated insulin secretion.

CONCLUSION:

This animal model responds well to 2 weight loss compounds with different mechanisms of action. Moreover, the gubra DIO-rat can be particularly useful for the testing of compounds with potential effects on diet preference.

• Authors: Gitte Hansen, Jacob Jelsing, Niels Vrang
• Journal: Acta pharmacologica Sinica (Acta Pharmacol Sin) Vol. 33 Issue 2 Pg. 194-200 (Feb 2012) ISSN: 1745-7254 [Electronic] United States
• PMID: 22301859 (Publication Type: Journal Article)

Chemical References

• Anti-Obesity Agents
• Cyclobutanes
• Liraglutide
• Glucagon-Like Peptide 1
• sibutramine

Topics

• Animals
• Anti-Obesity Agents (pharmacology, therapeutic use)
• Body Weight (drug effects)
• Cyclobutanes (pharmacology, therapeutic use)
• Eating (drug effects)
• Glucagon-Like Peptide 1 (analogs & derivatives, pharmacology, therapeutic use)
• Glucose Tolerance Test
• Insulin Resistance
• Liraglutide
• Male
• Obesity (drug therapy)
• Rats
• Rats, Sprague-Dawley